Replies to post #177325 on Biotech Values

[oc631]

There are lots of checks to cut. NOT cutting the checks for these near-cure drugs for HCV will mean cutting other checks for direct costs and comorbidities.

The dramatic rise and fall of telaprevir and boceprevir are stark examples of doctors and patients delaying treatment. Payers and politicians claim the system can't handle the costs going forward while the former "warehousing" crowd crows about the dangers (or costs) of delayed treatment. They will all find a middle ground. Parity pricing with minimal discounting would be snubbing a very powerful lobby.

[jbog]

zip,

Do you know the percentage of hcv positive patients that do not progress into the treatable range?

tks